Business Context and Reporting Period
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) filed a Form 8-K on March 21, 2025, reporting the entry into a material definitive agreement. The company is an emerging growth company incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figure disclosed is a contractual obligation of $260,000 related to a new consulting agreement.
Material Changes
The primary material change is the execution of a six-month Consulting Agreement with Bowery Consulting Group Inc., effective March 21, 2025. The agreement outlines services including research, due diligence, partnership analysis, market messaging, and capital raising strategies.
Guidance, Outlook, and Risks
- Payment Condition: The $260,000 fee for the consulting services is contingent upon the Company fully regaining compliance with Nasdaq Listing Rules.
- Strategic Focus: Management is focusing on scaling activities, developing growth strategies, and minimizing costs associated with technological platform improvements and marketing.
- Leadership: The report was signed by Chris Cooper, Interim Co-Chief Executive Officer.
Investor Verification Checklist
- Verify the Company's current status regarding Nasdaq Listing Rules compliance, as this triggers the $260,000 payment obligation.
- Review the full text of the Consulting Agreement (Exhibit 10.1) for specific performance milestones and termination clauses.
- Monitor subsequent filings for updates on capital raising strategies and partnership affiliations mentioned in the agreement.
- Confirm the timeline for the six-month term and any potential extensions.